Diabetes

Empagliflozin May Reduce Cardiovascular Mortality in T2D With LVH

Empagliflozin May Reduce Cardiovascular Mortality in T2D With LVH

By

For patients with T2D and left ventricular hypertrophy, empagliflozin reduced the risk for cardiovascular death vs placebo.

Higher Exposure to CVD Risk Factors in Women vs Men Who Have Diabetes

Higher Exposure to CVD Risk Factors in Women vs Men Who Have Diabetes

By

Compared with men, women in whom diabetes develops experience greater changes in the cumulative burden of cardiovascular risk factors from young to middle-age adulthood, which may contribute to a higher risk for CVD events.

Treating Albuminuria Reduces Cardiovascular Events in Type 2 Diabetes

Treating Albuminuria Reduces Cardiovascular Events in Type 2 Diabetes

By

Suppressing albuminuria should be an important target of therapy, according to investigators.

Glycemic Variability May Predict Incident Cardiovascular Disease, Mortality

Glycemic Variability May Predict Incident Cardiovascular Disease, Mortality

By

The researchers' findings contribute to a growing body of evidence regarding the prognostic value of glycemic variability.

Comprehensive Cardiovascular Risk Factor Control Lacking in Diabetes

Comprehensive Cardiovascular Risk Factor Control Lacking in Diabetes

By

Only 1 in 5 adults with diabetes achieved control over multiple risk factor targets for atherosclerotic cardiovascular disease.

How Does Cardiorespiratory Fitness Affect the Risk for T2D?

How Does Cardiorespiratory Fitness Affect the Risk for T2D?

By

An inverse dose-dependent association exists between cardiorespiratory fitness and type 2 diabetes risk.

Association Position Paper: Exercise Training for Patients With T2D and CVD

Association Position Paper: Exercise Training for Patients With T2D and CVD

Physicians need to take an active role in prescribing specific exercise training in patients with both type 2 diabetes mellitus and cardiovascular disease.

Linagliptin and Cardiovascular Events in Patients With Type 2 Diabetes

Linagliptin and Cardiovascular Events in Patients With Type 2 Diabetes

By

Investigators evaluated the effect of linagliptin vs placebo on cardiovascular and kidney disease outcomes in patients with T2D at high risk for cardiovascular and renal events.

Statin Therapy Reduces Risk for Diabetic Retinopathy in Type 2 Diabetes

Statin Therapy Reduces Risk for Diabetic Retinopathy in Type 2 Diabetes

Reduced risk, slowed progression of retinopathy for Taiwanese patients with type 2 diabetes, dyslipidemia

Non-Invasive Skin Autofluorescence Measurement May Predict CVD

Non-Invasive Skin Autofluorescence Measurement May Predict CVD

Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease, and mortality in the general population

Certain SGLT2 Inhibitors Significantly Decreased ASCVD Risk in T2D

Certain SGLT2 Inhibitors Significantly Decreased ASCVD Risk in T2D

Certain SGLT2 inhibitors and glucagon-like peptide 1 receptor agonists demonstrate significant cardiovascular benefits.

Ezetimibe Plus Statin Therapy Reduces Ischemic Risk in Polyvascular Disease, T2D

Ezetimibe Plus Statin Therapy Reduces Ischemic Risk in Polyvascular Disease, T2D

By

The addition of ezetimibe to simvastatin reduced ischemic risk compared with placebo, with consistent relative risk reductions in patients with and without polyvascular disease.

Skin Disease and Metabolic Syndrome: Early Warning Signs of a Greater Problem

Skin Disease and Metabolic Syndrome: Early Warning Signs of a Greater Problem

By

Skin disorders, particularly those with known inflammatory mechanisms, may be considered potential early markers for the development of insulin resistance leading to metabolic syndrome, type 2 diabetes, and cardiovascular disease.

Predicting Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes

Predicting Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes

By

Hyperglycemia, obesity, and hypertriglyceridemia are negatively related to cardiovascular autonomic neuropathy indices.

Liraglutide Labeling Updated With Cardiovascular Safety Data

Liraglutide Labeling Updated With Cardiovascular Safety Data

By

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non-fatal stroke, CV death) in patients treated with liraglutide 1.8mg once daily or placebo.

Metformin May Improve Vascular Health in Adolescents With Type 1 Diabetes

Metformin May Improve Vascular Health in Adolescents With Type 1 Diabetes

By

Metformin improved insulin resistance regardless of baseline BMI in adolescents with type 1 diabetes.

Bariatric Surgery Reduces Macrovascular Complications in Obesity, T2D

Bariatric Surgery Reduces Macrovascular Complications in Obesity, T2D

Lower composite incidence of macrovascular events, lower incidence of coronary artery disease at 5 years

Lorcaserin Decreases Incident Diabetes Risk in Overweight Patients

Lorcaserin Decreases Incident Diabetes Risk in Overweight Patients

Lorcaserin reduces the risk for diabetes in obese or overweight patients with prediabetes or without diabetes and reduces HbA1c among those with diabetes.

LVAD in Heart Failure Linked to Improved Glycemic Control

LVAD in Heart Failure Linked to Improved Glycemic Control

By

HbA1c levels following left ventricular assist device implantation were statistically significantly lower than before surgery.

Should Intensive BP Treatment Be Generalized to Adults With Diabetes?

Should Intensive BP Treatment Be Generalized to Adults With Diabetes?

By

Intensive blood pressure therapy is associated with a significantly lower risk for serious cardiovascular events in the adults with diabetes.

Trends in Cardiovascular Deaths for US Adults With and Without Diabetes

Trends in Cardiovascular Deaths for US Adults With and Without Diabetes

By

Investigators used data from the National Health Interview Survey and follow-up mortality data to estimate trends and disparities in CVD.

Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared

Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared

By

The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.

Higher Aldosterone Levels Tied to Incident Type 2 Diabetes Risk

Higher Aldosterone Levels Tied to Incident Type 2 Diabetes Risk

Racial/ethnic differences were seen in the association of aldosterone with incident type 2 diabetes.

Widespread Statin Use Not Recommended in Old, Very Old

Widespread Statin Use Not Recommended in Old, Very Old

No benefit in healthy elderly patients; the protective effect is limited to those with type 2 diabetes aged 75 to 84 years.

WHO Issues Recommendations for T2DM Treatment Intensification

WHO Issues Recommendations for T2DM Treatment Intensification

WHO has also made recommendations for type of insulin for type 1 and type 2 diabetes in low-resource settings.

Evaluating Excess Risk for Heart Failure Hospitalization in Type 2 Diabetes

Evaluating Excess Risk for Heart Failure Hospitalization in Type 2 Diabetes

By

Investigators examined the excess risk for heart failure in patients with type 2 diabetes and compared the risk with that in the general population without diabetes.

Assessing the Evidence of Aspirin for Primary Prevention in Diabetes

Assessing the Evidence of Aspirin for Primary Prevention in Diabetes

By

The substantial burden of cardiovascular disease in patients with diabetes has led to the exploration of various cardiovascular disease prevention strategies, including the use of aspirin.

Low Rates of Increasing Statin Doses After MI in Diabetes

Low Rates of Increasing Statin Doses After MI in Diabetes

By

Up-titration to a high-intensity statin occurred in only 37.7% of patients with diabetes after an acute myocardial infarction.

Inflammation and Endothelial Stress Associated With CV Risk in Type 2 Diabetes With Manifest CVD

Inflammation and Endothelial Stress Associated With CV Risk in Type 2 Diabetes With Manifest CVD

By

The risk for cardiovascular events in patients with type 2 diabetes without manifest cardiovascular disease is primarily related to the severity of atherosclerosis.

Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population

Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population

By

Investigators sought to compare cardiovascular risk and disease prevalence in the Hispanic and Latina population in the United States with and without a history of gestational diabetes.

Sign Up for Free e-Newsletters